Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...
Developing brand-new drugs is difficult, risky, and expensive. There is the pre-clinical stage, where novel clinical compounds are tested on laboratory animals. Then, provided results are positive, ...
Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results